• Artificial blood to made act as a substitute for red blood cells. While true blood perform different functions but artificial blood is designed for the purpose of transporting oxygen and carbon dioxide through the body.
• Perfluorocarbon emulsions are based on inert components which replace hydrogen and fluorine. Hemoglobin-based oxygen carriers consist of hemoglobin derived products sourced from human blood, bovine blood, microorganisms, and transgenic animals
• As per the 2011 analysis from the national blood collection and utilization survey, the US could see a shortfall of around 4 million units of blood annually by 2030.
• According to the National center for biotechnology information in 2019, estimated that annual incidence of the shock of any etiology is 0.3- 0.7 per 1000 cases with hemorrhagic shock being the most common in the intensive care unit.
• Major factors hindering the global artificial blood market during the forecast period are expansive, lack of awareness and adverse side effects associated with the usage of the artificial blood.
• Global artificial blood market is segmented by product type, by source, by application, and by distribution channel. By product, type includes hemoglobin-based oxygen carriers and perfluorocarbon emulsion, and by source includes human hemoglobin, animal hemoglobin, stem cells, synthetic polymers, and others.
• Hemoglobin-based oxygen carriers dominate the global artificial blood market during the forecast period owing to its extended product portfolio by key players compared with the perfluorocarbon emulsions, key players investing in the development of advanced hemoglobin-based oxygen carrier’s majority of them are in clinical trials.
• North America dominates the global artificial blood market during the forecast period owing to the rise in trauma deaths due to excessive blood loss prior to the admission, increase in the prevalence of anemia and blood-related disorders across the region and leading to the development of novel artificial blood.
• According to Health 24 in 2016, more than 20,000 trauma deaths in the united states occur due to the blood prior to arriving at the treatment center.
• In February 2019, Seattle Based medical technology company Healionics raised 3.8 million in funding to support the development of an artificial blood vessel called STARgraft for patients who undergo dialysis treatment.
Major market players in the artificial blood market are
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
